Clinical trials struggle to garner substantial participant numbers, a predicament that negatively impacts the public.
Clinical trials play a crucial role in the advancement of medicine, with research ongoing in various areas, from cancer to multiple sclerosis. However, participation in these trials remains low, with only about 3% of adult patients with cancer participating, according to Dr. Julie M. Vose, the immediate past-president of the American Society of Clinical Oncology.
Several factors contribute to this low participation rate. Demographic and socioeconomic barriers, geographical and logistical issues, communication and health literacy challenges, trial design and operational constraints, system-level misalignments, underrepresentation, and trust issues all pose significant hurdles.
Underrepresented groups often face cultural, language, and literacy challenges that limit engagement with trial materials and participation. Distance from trial sites, travel costs, inflexible visit schedules, and caregiving responsibilities reduce participation feasibility, particularly for rural or disadvantaged populations. Limited health literacy and lack of culturally or linguistically appropriate information hinder understanding and consent processes. Strict data requirements, rigid in-person visits, and complex protocols decrease accessibility and engagement, especially for older adults and socioeconomically disadvantaged groups.
Lack of coordination among funders, regulators, clinicians, and patients can result in trials that do not address patient priorities or facilitate community engagement. Low enrollment from diverse populations due to historical mistrust and inadequate outreach impairs generalizability and equity.
To increase their chances of being accepted into relevant clinical trials, patients can utilize digital self-screening tools, engage with healthcare providers, leverage telemedicine and decentralized trial options, seek out sites and trials committed to diverse enrollment, stay informed and proactive, and target trials designed for broad inclusion.
Reducing barriers to participation requires trial innovations such as flexible scheduling, cost coverage, multilingual digital tools, decentralized trial models, and community partnerships. Simultaneously, patients benefit from utilizing technology-enabled screening, collaborating with providers, and being proactive in their search for trials.
Vicky Carr, a breast cancer survivor turned patient advocate, counsels current patients about the various aspects of clinical trials and tells them that clinical trials are available to women at all stages of the breast cancer journey. People interested in participating in clinical trials can consult a significant number of online resources dedicated to connecting patients with studies, such as ClinicalTrials.gov, maintained by the National Institute of Health.
One such trial that is currently seeking participants is GeneMatch, which is looking for healthy people aged 55-75 to participate in Alzheimer's-related studies. Another trial is looking for veterans with post-traumatic stress disorder (PTSD) to match trained service dogs with them to see how the pups affect quality of life and activity.
Clinical trials often cover travel and hotel expenses for participants, ensuring that geographical barriers do not prevent those in need from accessing potentially life-saving treatments. Dave Bexfield, a resident of Albuquerque, New Mexico, who was diagnosed with multiple sclerosis in 2006, can attest to this. He participated in a clinical trial sponsored by the National Institutes of Health that involved a stem cell transplant in 2009. Bexfield says the trial saved his life. Within a few months of completion in 2010, he could walk again unaided.
However, not everyone is as fortunate as Bexfield. Teresa, a woman Carr counsels, had a limited income and could not afford to travel for a trial that could have helped her. She eventually passed away. This underscores the importance of reducing barriers to participation and increasing accessibility to clinical trials for all.
In conclusion, clinical trials are vital to the progress of medicine, but their potential is not being fully realised due to various barriers. By addressing these challenges, we can ensure that clinical trials are accessible to all, and that everyone has the opportunity to benefit from the latest medical advancements.
- Despite the crucial role of clinical trials in the advancement of medical conditions like multiple sclerosis and cancer, only a small fraction of affected individuals participate.
- Cultural, language, and literacy challenges, geographical and logistical issues, and strict data requirements are some factors that reduce engagement with clinical trials.
- Underrepresented groups face significant hurdles in participating due to factors such as limited health literacy, caregiving responsibilities, and inflexible visit schedules.
- To increase accessibility to clinical trials, innovations like flexible scheduling, cost coverage, multilingual digital tools, and community partnerships are required.
- Patients can benefit from utilizing technology-enabled screening, collaborating with healthcare providers, and being proactive in their search for trials.
- Case studies like Dave Bexfield, who was saved by a clinical trial for multiple sclerosis, highlight the crucial role of clinical trials in providing life-saving treatments, while tragic stories like Teresa's underscore the need to reduce barriers and increase accessibility for all.
